Is PRLD or PTCT more undervalued in 2026?

CirclFi compares Prelude Therapeutics Incorporat (PRLD) and PTC Therapeutics, Inc. (PTCT) using 13 institutional-grade valuation models. PRLD has a Quality of Company score of 5.9/10 while PTCT scores 4.1/10.

Which is a better buy — PRLD or PTCT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PRLD and PTCT valuations compare?

PRLD at $3.92 and PTCT at $73.85 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PRLD vs PTCT Valuation Comparison 2026 — Intrinsic Value Analysis

PRLD

Pharmaceutical Preparations

Prelude Therapeutics Incorporat

Quality

5.9

out of 10

Value Trap

SAFE

Price

$3.92

Last close

Models

9/13

Active

PTCT

Pharmaceutical Preparations

PTC Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$73.85

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	PRLD Fair Value	PRLD Upside	PTCT Fair Value	PTCT Upside
Bayesian DCF	Intrinsic	$1.25	-68.2%	$24.91	-66.3%
Earnings Power Value	Intrinsic	—	—	$125.45	+88.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.75	-55.4%	$22.29	-66.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PRLD vs PTCT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PRLD vs PTCT — Which Stock Is More Undervalued?

PRLD scores higher with a 5.9/10 quality rating vs PTCT's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Prelude Therapeutics Incorporat (PRLD) and PTC Therapeutics, Inc. (PTCT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PRLD currently trades at $3.92 with a QOC of 5.9/10, while PTCT trades at $73.85 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).